Warfarin safety and efficacy in patients with thoracic aortic plaque and atrial fibrillation. SPAF TEE Investigators. Stroke Prevention and Atrial Fibrillation. Transesophageal echocardiography

Am J Cardiol. 1999 Feb 1;83(3):453-5, A9. doi: 10.1016/s0002-9149(98)00886-8.

Abstract

Patients with atrial fibrillation and with documented aortic plaque who were assigned to adjusted-dose warfarin therapy (international normalized ratio 2.0 to 3.0) had an annual rate of cholesterol embolization of 0.7% (95% confidence interval [CI] 0.1% to 5.3%/patient-year). Warfarin-assigned patients with plaque had a lower rate of embolic events (5.9%/year; 95% CI 3.0 to 12) than those on combination low-dose warfarin (international normalized ratio <1.5) plus aspirin (17.3%/year; 95% CI 11 to 27; p = 0.01).

Publication types

  • Clinical Trial
  • Clinical Trial, Phase III
  • Comparative Study
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Aged
  • Anticoagulants / therapeutic use*
  • Aorta, Thoracic / diagnostic imaging
  • Aortic Diseases / complications
  • Aortic Diseases / diagnostic imaging
  • Aortic Diseases / drug therapy*
  • Arteriosclerosis / complications
  • Arteriosclerosis / diagnostic imaging
  • Arteriosclerosis / drug therapy
  • Aspirin / therapeutic use
  • Atrial Fibrillation / complications
  • Atrial Fibrillation / diagnostic imaging
  • Atrial Fibrillation / drug therapy*
  • Drug Therapy, Combination
  • Echocardiography, Transesophageal
  • Female
  • Fibrinolytic Agents / therapeutic use
  • Follow-Up Studies
  • Humans
  • Safety
  • Thromboembolism / complications
  • Thromboembolism / diagnostic imaging
  • Thromboembolism / drug therapy*
  • Treatment Outcome
  • Warfarin / therapeutic use*

Substances

  • Anticoagulants
  • Fibrinolytic Agents
  • Warfarin
  • Aspirin